NCT04902365

Brief Summary

Visual snow (VS) is a distressing, life-impacting condition with unrelenting and persistent disturbing visual phenomena. Disease onset is usually around age 20 and is characterized by continuous perception of innumerable flickering dots (like a 'broken television'). The disease is often accompanied by comorbidities such as migraine, tinnitus, depression and anxiety. Neuronally, VS patients show cerebral hypermetabolism, resulting in altered neuronal excitability, as well as increased grey matter volume in parts of the visual cortex. For this pilot study, the investigators aim to recruit VS patients. In a double-blind, randomized and placebo-controlled longitudinal experiment, the investigators will use real-time functional magnetic resonance imaging (rtfMRI) neurofeedback to teach patients to downregulate activity in different regions of the visual cortex. The investigators hypothesize that neurofeedback will allow patients to learn to downregulate their abnormal visual cortex activity. Moreover, the investigators predict that a stronger downregulation of activity from the lingual gyrus will correlate with a more pronounced decrease in VS symptoms.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
70

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Jan 2022

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 20, 2021

Completed
6 days until next milestone

First Posted

Study publicly available on registry

May 26, 2021

Completed
8 months until next milestone

Study Start

First participant enrolled

January 14, 2022

Completed
1.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 30, 2023

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 30, 2023

Completed
Last Updated

June 15, 2023

Status Verified

June 1, 2023

Enrollment Period

1.6 years

First QC Date

May 20, 2021

Last Update Submit

June 12, 2023

Conditions

Keywords

neurofeedbackreal-time functional magnetic resonance imaging

Outcome Measures

Primary Outcomes (1)

  • symptom severity

    Changes in symptom severity before and after real-time fMRI neurofeedback

    Acute after neurofeedback and 3 months after neurofeedback

Secondary Outcomes (1)

  • Magnetic resonance imaging

    before and immediately after the neurofeedback sessions

Study Arms (2)

Patients group 1

ACTIVE COMPARATOR

This group will regulate a brain region by real-time functional magnetic resonance imaging that is centrally involved in the visual snow syndrome

Other: neurofeedback

Patients group 2

PLACEBO COMPARATOR

This group will regulate a brain region by real-time functional magnetic resonance imaging that is not centrally involved in the visual snow syndrome

Other: neurofeedback

Interventions

(based on real-time functional magnetic resonance signals)

Patients group 1Patients group 2

Eligibility Criteria

Age18 Years - 60 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Patients with VS (≥ 18 to ≤ 60 years), which can read and sign the informed consent form.
  • Male and female
  • Healthy controls (≥ 18 to ≤ 60 years), which can read and sign the informed consent form.

You may not qualify if:

  • pregnant participants
  • participants suffering from a degenerative disorder of the Central Nervous System, such as Stroke, Multiple Sclerosis, Parkinson's Disease, Alzheimer's Disease and Huntington's Disease and with major psychiatric disorders such as schizophrenia, depression, or anxiety disorder requiring pharmacological treatment (psycho-pharmaca).

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University Hospital Zurich

Zurich, 8091, Switzerland

Location

MeSH Terms

Conditions

visual snow syndrome

Interventions

Neurofeedback

Intervention Hierarchy (Ancestors)

Biofeedback, PsychologyMind-Body TherapiesComplementary TherapiesTherapeuticsBehavior TherapyPsychotherapyBehavioral Disciplines and ActivitiesFeedback, Psychological

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Masking Details
Double Blind
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: In a double-blind, randomized and placebo-controlled longitudinal experiment, the investigators will use real-time functional magnetic resonance imaging (rtfMRI) neurofeedback to teach patients to downregulate activity in different regions of the visual cortex. 50 patients (25 in each arm)
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 20, 2021

First Posted

May 26, 2021

Study Start

January 14, 2022

Primary Completion

August 30, 2023

Study Completion

December 30, 2023

Last Updated

June 15, 2023

Record last verified: 2023-06

Locations